July 14, 2020

The Niche

Knoepfler lab stem cell blog

regenerative medicine

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More

2 min read

Sometimes we could all use a jolt of good news and cool science. Those of us in the stem cell field probably get tired at times of all the bad-ish, even if important news (like this from Michael Hiltzik of the LA Times) out there surrounding certain unproven stem cell offerings and also clinics that engage in all kinds of stuff ranging from off-beat shenanigans to really dark stuff. Today’s post is focused mostly on the good news and exciting science. You can see …Read More

2 min read

How does one keep up with all the regenerative medicine and stem cell happenings? There is always something happening in the stem cell and regenerative medicine field ranging from science to policy matters. This post is an update on some recent stem cell happenings that I see as notable or interesting. New Pubs Direct reprogramming pub. One of the more interesting recent papers was from direct reprogramming guru Marius Wernig as his team came out with a new transdifferentiation paper that strikingly reports conversion …Read More

3 min read

There are now so many clinics selling non-FDA approved stem cell offerings across the U.S. that tens or hundreds of thousands of patients are at risk. How did we get here? What if we had a way of understanding how stem cell clinics spread across the U.S. in the first place? For example, an animated map showing the spread of stem cell clinics selling non-FDA approved “treatments” across the U.S. would be useful. With publication of our new paper, the recent work of Leigh Turner …Read More